Drugs / EPAFIPASE
EPAFIPASE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00037687 | Apr 2001 → Dec 2004 | infectious disease with sepsis | ICOS Corporation | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPAFIPASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108402 ↗ |
| Known as | Epafipasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108402 ↗ |
| Known as | Pafase | “Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®)” NCT00037687 ↗ |
| Known as | Recombinant Platelet-Activating Factor Acetylhydrolase | “Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®)” NCT00037687 ↗ |
| Known as | rPAF-AH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00037687 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human Platelet-Activating Factor Acetylhydrolase” NCT00037687 ↗ |
| Route | Intravenous | “administered daily for five consecutive days by intravenous (IV) infusion” NCT00037687 ↗ |